Press Release

Servier To Acquire a Potential Best-in-Class Precision Therapy for Acute Leukemias, from BioNova Pharmaceuticals

- **BN104 acquisition strengthens Servier's leadership in blood cancer and commitment to developing precision medicine in line with its 2030 strategy**

Suresnes (France), May 23, 2025 – Servier, an independent global pharmaceutical group governed by a non-profit foundation, and BioNova Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today announce that the companies have entered into a definitive agreement under which Servier will acquire BN104, a potential best-in-class menin inhibitor currently in Phase 1/2 development for the treatment of acute leukemias.

"At Servier, we are committed to advancing transformative treatments for patients with rare cancers and high unmet medical needs. BioNova's asset in acute leukemia is a natural fit with our oncology focus on developing targeted therapies for genetically defined patient populations. This acquisition further enhances our leadership position in blood cancers, adding to our development pipeline in hematological malignancies" **said Claude Bertrand, Executive Vice-President of R&D at Servier**.

"Servier brings deep scientific expertise and a strong track record in the global development of targeted oncology therapies, making them well-positioned to advance BN104 for patients with acute leukemia. With their global reach and commitment to precision medicine, we believe they are the right partner to unlock the full potential of this asset and deliver meaningful impact for patients worldwide" **said Ye HUA, MD, CEO and Founder of BioNova Pharmaceuticals**.

In line with its 2030 strategy, Servier aims to accelerate the global clinical development of BN104 in mutated AML as well as acute lymphoblastic leukemia (ALL) where the unmet medical need is high, especially for safer therapies in relapse/refractory conditions. This asset will enable Servier to further expand its hematological oncology franchise and build on its leadership with a targeted and differentiated portfolio of medicines in this field.

BN104 is a novel, potent and highly selective small molecule designed and discovered by BioNova Pharmaceuticals. BN104 is uniquely positioned to be a potential best-in-class menin inhibitor for the treatment of acute leukemias with a KMT2A gene rearrangement or NPM1 mutation. Results presented at the 2024 American Society of Hematology (ASH) Annual Meeting demonstrated that patients with relapse refractory Acute Myeloid Leukemia (AML) had a CR/CRh (complete response/complete response with partial hematologic recovery) rate of 60.9% for the KMT2A rearranged subgroup and 40% for the NPM1 mutation subgroup, with a tolerable safety profile[1] (no QTc prolongation nor differentiation syndrome ≥G3). KMT2A rearrangements are found in 5 to 10%[2] of patients with AML and NPM1

[1] https://ashpublications.org/blood/article/144/Supplement%201/2879/533203/A-First-in-Human-Phase-1-2-Study-of-the-Menin and ASH 2024 poster 2879

[2] Zhang R., et al., Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group. Blood Cancer J. 2025 May 2;15(1):84. doi: 10.1038/s41408-025-01293-x

mutations in 20 to 30%[3] of patients with AML. BN104 was granted Orphan Drug Designation (ODD) in April 2023 and Fast Track Designation in October 2023 by the U.S. Food and Drug Administration (FDA) for the treatment of acute leukemia.

Under the terms of the agreement, BioNova Pharmaceuticals will receive a cash payment for its sale of BN104 with development and regulatory earn-outs. The transaction is subject to customary closing conditions.

Servier Contact

For Media: presse@servier.com

About Servier

Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.
Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development.

As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence & control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective.

Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine.

To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice.

Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion.

More information on: servier.com. Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

[3] Falini B., Dillon R., Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML. Blood Cancer Discov. 2023 Dec 7;5(1):8–20. doi: 10.1158/2643-3230.BCD-23-0144